Want to see SE:ONCO full AI Analyst Report?

Oncopeptides AB (ONCO) Price & Analysis

9 Followers

ONCO Stock Chart & Stats

kr1.60

kr0.04(2.18%)

At close: Jul 27 4:00 PM EDT

kr1.60

kr0.04(2.18%)

Day’s Range― - ―

52-Week Rangekr1.26 - kr6.18

Previous CloseN/A

Volume1.31M

Average Volume (3M)2.28M

Market Cap

kr647.57M

Enterprise Valuekr305.43

Total Cash (Recent Filing)kr205.15M

Total Debt (Recent Filing)kr130.80M

Price to Earnings (P/E)―

Beta0.07

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.94

Shares Outstanding381,148,130

10 Day Avg. Volume1,913,694

30 Day Avg. Volume2,284,999

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)-18.53

Price to Sales (P/S)15.35

P/FCF Ratio-4.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.44

Revenue Forecast (FY)kr141.30M

Bulls Say, Bears Say

Bulls Say

Improving RevenueRevenue growth indicates improving commercial traction for Oncopeptides’ oncology portfolio. Sustained expansion would provide a larger base over which the company can spread its development, regulatory, and commercial costs.

Exceptional Gross MarginThe exceptionally high gross margin is consistent with the economics of a differentiated pharmaceutical product. If maintained as sales scale, it could support meaningful operating leverage once spending and infrastructure become better aligned with revenue.

Narrowing LossesLosses remain substantial, but the improvement in net margin suggests some progress toward a more sustainable earnings profile. Continued reduction in losses would lower the company’s dependence on external funding over time.

Bears Say

Severe Cash BurnPersistent negative operating and free cash flow shows that current operations do not fund the business. Continued cash consumption increases refinancing or dilution risk and may constrain investment in commercialization and pipeline development.

Elevated LeverageHigh leverage is challenging for a company that remains loss-making and cash-flow negative. Debt obligations reduce financial flexibility, while the need for continued funding access could weaken negotiating power with lenders or investors.

Large Operating LossesThe cost base remains far larger than the company’s current revenue, leaving Oncopeptides well short of break-even. Unless revenue scales materially or expenses fall, profitability and self-sustaining operations remain distant.

Oncopeptides AB News

Oncopeptides to Present Q2 2026 Results as Oncology Commercialization Expands

An announcement from Oncopeptides AB ( ($SE:ONCO) ) is now available. Oncopeptides AB, a Stockholm‑listed biotech focused on...

19h ago

Oncopeptides Secures Slovenian List Price for Pepaxti in First CEE Expansion Step

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides has secured a maximum allowed list...

4d ago

Oncopeptides Updates Share and Vote Structure After Incentive Share Conversion

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides AB has adjusted its share structure...

2M ago

Oncopeptides Enrolls First Patient in Pioneering Glioblastoma PDC Trial

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides has enrolled the first patient in its OP-701...

2M ago

Oncopeptides seeks EMA approval to move Pepaxti into earlier-line multiple myeloma treatment

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides has submitted a Type II variation application to...

2M ago

Oncopeptides launches German real-world study to bolster Pepaxti’s myeloma profile

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides has enrolled the first patient in its MARINA...

2M ago

Oncopeptides to spotlight Pepaxti data and PDC strategy at EHA 2026

Oncopeptides AB ( ($SE:ONCO) ) has provided an update. Oncopeptides AB will showcase an extensive data package on...

3M ago

Oncopeptides Accelerates CEE Expansion for Pepaxti via Exclusive Salus Distribution Deal

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides AB has signed an exclusive agreement...

3M ago

Oncopeptides AGM Backs Incentive Schemes and Expands Capital-Raising Mandate

Oncopeptides AB ( ($SE:ONCO) ) has provided an announcement. Oncopeptides’ Annual General Meeting approved the 2025 annual report,...

3M ago

Oncopeptides’ Pepaxti Shows Strong Phase 2 Data in Myeloma Patients With Renal Impairment

Oncopeptides AB ( ($SE:ONCO) ) has shared an update. Oncopeptides has reported Phase 2 BRIDGE study results showing...

3M ago

ONCO FAQ

What was Oncopeptides AB’s price range in the past 12 months?

Oncopeptides AB lowest stock price was kr1.25 and its highest was kr6.18 in the past 12 months.

What is Oncopeptides AB’s market cap?

Oncopeptides AB’s market cap is kr647.57M.

When is Oncopeptides AB’s upcoming earnings report date?

Oncopeptides AB’s upcoming earnings report date is Aug 27, 2026 which is in 6 days.

How were Oncopeptides AB’s earnings last quarter?

Oncopeptides AB released its earnings results on May 13, 2026. The company reported -kr0.12 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Oncopeptides AB overvalued?

According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Oncopeptides AB pay dividends?

Oncopeptides AB does not currently pay dividends.

What is Oncopeptides AB’s EPS estimate?

Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oncopeptides AB have?

Oncopeptides AB has 381,148,130 shares outstanding.

What happened to Oncopeptides AB’s price movement after its last earnings report?

Oncopeptides AB reported an EPS of -kr0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 38.715%.

Which hedge fund is a major shareholder of Oncopeptides AB?

Currently, no hedge funds are holding shares in SE:ONCO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Oncopeptides AB

Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.